NeoGenomics (NEO) CEO Chris Smith to retire
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/30/2026
- Wall St set for strongest quarter in years as risk appetite holds despite US-Iran war
- Dollar pushes higher, yen sinks to 40-year low
- NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
- Citi says bearish flows are building in Nasdaq and S&P 500
- Patrick and LCI Industries to merge in all-stock deal
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- EchoStar Prepares Dish DBS Bankruptcy Filing as Soon as Tuesday - WSJ
- Strategy stock jumps 7% as firm shifts to active capital management
- New leader board: Citi refreshes AI compute semiconductor picks
- Honeywell completes aerospace spin-off, splits into 3 companies
NeoGenomics Announces Chief Executive Officer Succession
January 10, 2025 7:05 AM ESTChris Smith to retire effective April 1, 2025; Board Member Tony Zook named incoming CEO
Company reaffirms Fiscal 2024 financial guidance
FT. MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NeoGenomics or the Company) (NASDAQ: NEO), a leading oncology testing services company, today announced that Chris Smith will retire as Chief Executive Officer (CEO) and board member effective April 1, 2025. Tony Zook, an independent board member since 2023, will assume the role of CEO at that time.
Chris has provided exceptional leadership for NeoGenomics, joining the Company at a critical time and... More
